JP2002518417A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002518417A5 JP2002518417A5 JP2000555558A JP2000555558A JP2002518417A5 JP 2002518417 A5 JP2002518417 A5 JP 2002518417A5 JP 2000555558 A JP2000555558 A JP 2000555558A JP 2000555558 A JP2000555558 A JP 2000555558A JP 2002518417 A5 JP2002518417 A5 JP 2002518417A5
- Authority
- JP
- Japan
- Prior art keywords
- transport device
- prostaglandin
- therapeutic agent
- polymer
- delivery device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 239000004014 plasticizer Substances 0.000 description 6
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 5
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 5
- 229960000711 alprostadil Drugs 0.000 description 5
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 5
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 5
- MWKPHOIHTLQZIY-UHFFFAOYSA-N 2-hexyldecyl octadecanoate Chemical group CCCCCCCCCCCCCCCCCC(=O)OCC(CCCCCC)CCCCCCCC MWKPHOIHTLQZIY-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- -1 moxysilate Chemical compound 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 150000003180 prostaglandins Chemical group 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 2
- 229960001999 phentolamine Drugs 0.000 description 2
- 108060006613 prolamin Proteins 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical group O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010061711 Gliadin Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- HPXRVTGHNJAIIH-PTQBSOBMSA-N cyclohexanol Chemical class O[13CH]1CCCCC1 HPXRVTGHNJAIIH-PTQBSOBMSA-N 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960002006 linsidomine Drugs 0.000 description 1
- FKDHHVKWGRFRTG-UHFFFAOYSA-N linsidomine Chemical compound [N-]1OC(=N)C=[N+]1N1CCOCC1 FKDHHVKWGRFRTG-UHFFFAOYSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 229940005542 parasympathomimetics Drugs 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 239000000050 smooth muscle relaxant Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9067498P | 1998-06-25 | 1998-06-25 | |
| US60/090,674 | 1998-06-25 | ||
| PCT/US1999/014410 WO1999066870A1 (en) | 1998-06-25 | 1999-06-25 | A device and method for the treatment of erectile dysfunction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002518417A JP2002518417A (ja) | 2002-06-25 |
| JP2002518417A5 true JP2002518417A5 (https=) | 2006-07-20 |
Family
ID=22223792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000555558A Pending JP2002518417A (ja) | 1998-06-25 | 1999-06-25 | 勃起機能不全の治療装具及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1089679B1 (https=) |
| JP (1) | JP2002518417A (https=) |
| AT (1) | ATE303774T1 (https=) |
| AU (1) | AU765057B2 (https=) |
| CA (1) | CA2335736A1 (https=) |
| DE (1) | DE69927154T2 (https=) |
| HU (1) | HUP0103206A3 (https=) |
| IL (2) | IL140475A0 (https=) |
| NZ (1) | NZ509031A (https=) |
| PL (1) | PL345087A1 (https=) |
| WO (1) | WO1999066870A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6552024B1 (en) * | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| AU5907300A (en) | 1999-07-02 | 2001-01-22 | Procter & Gamble Company, The | Compositions comprising organosiloxane resins for delivering xylitol to the oralcavity |
| KR100402334B1 (ko) | 2000-06-23 | 2003-10-22 | 환인제약 주식회사 | 알프로스타딜 외용제 |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| WO2002017927A1 (en) * | 2000-08-30 | 2002-03-07 | Unimed Pharmaceuticals, Inc. | Method for treating erectile dysfunction and increasing libido in men |
| US6899897B2 (en) * | 2001-06-18 | 2005-05-31 | Jaleva, Inc. | Gum resin as a carrier for topical application of pharmacologically active agents |
| US8524200B2 (en) | 2002-09-11 | 2013-09-03 | The Procter & Gamble Company | Tooth whitening products |
| US20050181030A1 (en) * | 2003-01-03 | 2005-08-18 | Mo Y. J. | Topical stabilized prostaglandin E compound dosage forms |
| US6841574B2 (en) * | 2003-01-03 | 2005-01-11 | Nexmed Holdings, Inc. | Topical stabilized prostaglandin E compound dosage forms |
| MXPA05008142A (es) | 2003-01-31 | 2005-09-30 | Sankyo Co | Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension. |
| JP4157889B2 (ja) * | 2003-06-25 | 2008-10-01 | 有限会社 循環器研究所 | 性交機能改善用外用製剤 |
| US9554984B2 (en) | 2003-11-03 | 2017-01-31 | Jaleva Pharmaceuticals, Llc | Oral care compositions for topical application |
| CA2629810A1 (en) | 2005-11-07 | 2007-05-18 | Jaleva, Llc | Film-forming resins as a carrier for topical application of pharmacologically active agents |
| IT201600119871A1 (it) * | 2016-11-25 | 2018-05-25 | Sabatino Russo | Uso dell’associazione di inibitori della fosfodiesterasi 5 con prostaglandina e1 per il trattamento della disfunzione erettile |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4725439A (en) * | 1984-06-29 | 1988-02-16 | Alza Corporation | Transdermal drug delivery device |
| JPS61204117A (ja) * | 1985-03-07 | 1986-09-10 | Tooa Eiyoo Kk | 経皮吸収外用剤 |
| FI872552L (fi) | 1986-06-09 | 1987-12-10 | American Cyanamid Co | Prostaglandinkomposition foer lokalt bruk. |
| EP0266968A3 (en) * | 1986-11-03 | 1988-08-24 | Gérard G. Cohen | Gelled ointment of vasodilating agent |
| US4829991A (en) * | 1987-01-06 | 1989-05-16 | Medical Engineering Corp. | Method and device for stimulating an erection |
| SU1705319A1 (ru) * | 1987-10-23 | 1992-01-15 | Всесоюзный Научно-Исследовательский Институт Биотехнологии | Состав полимерной диффузионной матрицы дл трансдермального введени лекарственных веществ |
| US5242391A (en) | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
| IT1247678B (it) | 1990-05-31 | 1994-12-28 | Alberto Reale | Metodo per la cura dell'impotenza erettiva maschile |
| US5202125A (en) * | 1990-12-10 | 1993-04-13 | Theratech, Inc. | Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes |
| DE4117249C2 (de) | 1991-05-27 | 1998-05-14 | Christian Dr Stief | Linsidomin zur Behandlung erektiler Dysfunktionen |
| AU669492B2 (en) * | 1991-11-11 | 1996-06-13 | Hisamitsu Pharmaceutical Co., Inc. | Fomentation containing ketorolac |
| DE69326848T2 (de) * | 1992-05-13 | 2000-01-27 | Alza Corp | Oxybutynin zur transdermalen Verabreichung |
| US6007836A (en) * | 1993-05-28 | 1999-12-28 | Vericade, Inc. | Transdermal vasodilator |
| CA2161974A1 (en) * | 1993-05-28 | 1994-12-08 | Eric L. Denzer | Condom with transdermal vasodilator |
| US5333621A (en) * | 1993-05-28 | 1994-08-02 | Eric Denzer | Condom with transdermal vasodilator |
| GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| PT742011E (pt) * | 1994-11-17 | 2002-10-31 | Toray Industries | Preparacao que pode ser absorvida por via percutanea |
| FR2729296B1 (fr) * | 1995-01-12 | 1997-03-28 | Europlanaire | Compositions pharmaceutiques comprenant une superoxyde dismutase |
| US5741511A (en) * | 1995-04-12 | 1998-04-21 | Sam Yang Co., Ltd. | Transdermal drug delivery device for treating erectile dysfunction |
| FR2748658B1 (fr) * | 1996-05-15 | 2000-08-18 | Biotec Centre Sa | Utilisation de composes du type "alpha-bloquants" notamment le moxisylyte et/ou ses derives pour le traitement de dysfonctionnements erectiles par voie transmucosale balanique |
| WO1998017315A2 (en) * | 1996-10-24 | 1998-04-30 | Alza Corporation | Permeation enhancers for transdermal drug delivery compositions, devices, and methods |
-
1999
- 1999-06-25 JP JP2000555558A patent/JP2002518417A/ja active Pending
- 1999-06-25 HU HU0103206A patent/HUP0103206A3/hu unknown
- 1999-06-25 EP EP99930719A patent/EP1089679B1/en not_active Revoked
- 1999-06-25 WO PCT/US1999/014410 patent/WO1999066870A1/en not_active Ceased
- 1999-06-25 IL IL14047599A patent/IL140475A0/xx active IP Right Grant
- 1999-06-25 PL PL99345087A patent/PL345087A1/xx unknown
- 1999-06-25 NZ NZ509031A patent/NZ509031A/xx unknown
- 1999-06-25 CA CA002335736A patent/CA2335736A1/en not_active Abandoned
- 1999-06-25 AT AT99930719T patent/ATE303774T1/de not_active IP Right Cessation
- 1999-06-25 DE DE69927154T patent/DE69927154T2/de not_active Revoked
- 1999-06-25 AU AU47200/99A patent/AU765057B2/en not_active Ceased
-
2000
- 2000-12-21 IL IL140475A patent/IL140475A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002518417A5 (https=) | ||
| US6723781B1 (en) | Hydrogels containing substances | |
| US5750136A (en) | Bioadhesive composition and patch | |
| US5750134A (en) | Bioadhesive composition and patch | |
| Acarturk | Mucoadhesive vaginal drug delivery systems | |
| JP2004505931A5 (https=) | ||
| CN1509164A (zh) | 释放化妆品和药物的体系 | |
| JP2002536118A5 (https=) | ||
| JP2002524490A5 (https=) | ||
| JP2004501956A5 (https=) | ||
| JP2003533471A (ja) | 経皮薬剤送出用のヒドロゲル組成物 | |
| AU634598B2 (en) | Bioadhesive composition and patch | |
| JP2001233769A (ja) | 塩酸ブプレノルフィン含有貼付剤 | |
| KR20080080355A (ko) | 손·발톱용 의약 조성물 | |
| JPS60152413A (ja) | メントールにより経皮性薬剤放出の強化を行なつた局所用組成物 | |
| AU765057B2 (en) | A device and method for the treatment of erectile dysfunction | |
| MXPA06012655A (es) | Preparaciones topicas que contienen ambroxol. | |
| JP2002539149A5 (https=) | ||
| CA2121603A1 (en) | Antiphlogistic-analgesic plaster | |
| EP3586833A1 (en) | Transdermal patch base and transdermal patch using same | |
| US20240082172A1 (en) | Method for depot creation during transdermal drug delivery | |
| WO2002017979A2 (en) | Dehydrated hydrogels | |
| US7087240B1 (en) | Device and method for the treatment of erectile dysfunction | |
| JP7202441B2 (ja) | 冷却シート | |
| JP2811401B2 (ja) | パップ剤 |